By Michael Mooney, May, 2013
After several dozen years of skepticism and misunderstanding by the medical establishment, a study using intravenous (IV) vitamin C shows that vitamin C may, in fact, promote anticancer activity, but only when delivered in high enough concentrations to cancerous cells.
After two-time Nobel Prize winner, Linus Pauling proclaimed the potential for vitamin C to cure cancer in 1970, studies were conducted with oral vitamin C that showed no effect on cancer. It appears that the design of the studies, using orally delivered vitamin C, was the problem, not vitamin C itself.
Vitamin C needs to be delivered in high concentrations that are not possible with orally delivered tablets.
US Government researcher Dr. Mark Levine has stated this several years ago, but medical science moves slowly, especially when the focus is not a profitable drug, but a nutrient that no one can patent and profit from.
In fact, if a nutrient is effective, it is a competitor to drugs, so drug manufacturers have an incentive to work to make the nutrient look worthless and so we see data in the press that says that nutrients don't work, even when they have been shown to work. We also see erroneous studies that are created to reach a conclusion that the nutrient doesn't work or may even harm you.
(I've devoted an entire section of my web site to debunking this type of erroneous information, which you can view at: www.michaelmooney.net#corrections.)
Vitamin C in intravenous or liposomal form, which can each deliver high concentrations to cancerous cells, have been shown to work - to even cure cancer. See: http://www.michaelmooney.net/DidLiposomalVitaminCCureCancer.html
In the study this article focuses on, Robert Levin, MD and Christopher M Stephenson, DO, of Cancer Treatment Centers of America administered higher doses of intravenous vitamin C than had been used in previous studies.
This new study moves forward the information that's needed to utilize IV vitamin C to fight cancers, either alone or as an adjunct to conventional cancer therapies.
Indeed, a phase I clinical trial evaluated high dose IV-administered vitamin C combined with cancer drugs gemcitabine and erlotinib in nine patients with stage IV metastatic pancreatic cancer. High enough levels of vitamin C were achieved in the participants and tumor volumes decreased in eight out of nine patients.
Vitamin C as an anti-cancer agent has taken time being discovered, but we are finally seeing some mainstream recognition of its potential.
Disclaimer: The information contained in this publication is for educational purposes only, and is in no way a substitute for the advice of a qualified medical doctor, registered dietitian, certified nutritionist, or exercise physiologist. When you ask any health care professional to help you make decisions about your personal healthcare, I recommend that you show them the information you find here because they may not be aware of it and the scientific studies that support it. Appropriate medical therapy and the use of pharmaceutical or nutritional compounds should be tailored for the individual as no two individuals are alike. I do not recommend self-medicating with any compound as you should consult with a qualified medical doctor, preferably one who is knowledgeable about nutrition and complementary/functional medicine who can determine your individual situation. Any use of the information presented in this publication for personal medical therapy is done strictly at your own risk and no responsibility is implied or intended on the part of the contributing writers, or the publisher.